A study testing whether a GLP-1 medicine from Yale University, semaglutide, can help people drink less.
- Who can join
- Adults 18 to 99, have alcohol use disorder, BMI 23+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 17 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Alcohol Use Disorder (AUD). Also studied in: HIV.
Full scientific study title: Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide.
Who can join
Adults 18 to 99, have alcohol use disorder, BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- diagnosed with HIV
- Receive care at the Atlanta VA Healthcare System
- Age 18 or over
- Meet criteria for mild, moderate, or severe alcohol use disorder by the DSM-5 Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
- Have evidence of significant alcohol use: PEth > 20ng/ml
Key exclusion criteria
- Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
- Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
- Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment)
- Untreated moderate to severe opioid use disorder
- Residence out of state
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Georgia1 site
- Atlanta VA Medical CenterDecatur, Georgia
Timeline
Started enrolling: 2026-01-15. Expected completion: 2027-06-30. Last updated on ClinicalTrials.gov: 2026-03-24.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
